Jump to ingredient:

Dileucine (L-Leucyl-L-Leucine Monohydrate)

View the Dileucine product

What Is Dileucine?

Dileucine is a leucine dipeptide: two leucine molecules bonded together via a peptide linkage, forming L-Leucyl-L-Leucine Monohydrate. It is not a modified amino acid or a proprietary blend ingredient. It is a naturally occurring dipeptide that the body generates during protein digestion and that researchers have been studying for decades in the context of muscle protein metabolism.

The reason Dileucine is gaining attention in performance nutrition is not merely that it contains leucine, but that it may be absorbed via a different and potentially more efficient pathway than free-form leucine. Free amino acids, including L-Leucine, are absorbed primarily through sodium-dependent amino acid transporters. Dipeptides, by contrast, are absorbed through PepT1 (Peptide Transporter 1) and PepT2, which are high-capacity, low-affinity transporters capable of handling a large flux of substrate before becoming saturated. This distinction matters considerably when the goal is to deliver leucine rapidly and at high concentrations to muscle tissue.

Mechanism of Action

Leucine is the primary amino acid responsible for activating the mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway in skeletal muscle. mTORC1 is the central regulator of muscle protein synthesis (MPS). When leucine availability rises above a threshold concentration intracellularly, it activates the Rag GTPase complex, which recruits mTORC1 to the lysosomal surface where it is activated by Rheb. This triggers phosphorylation of downstream targets including p70S6 kinase and 4E-BP1, which together drive ribosomal translation of mRNA into new muscle protein.

The critical factor here is the rate and peak of leucine delivery to muscle tissue. Research indicates that a sharp, rapid rise in plasma leucine concentrations is more effective at triggering mTORC1 activation than a slow, sustained rise. This is known as the "leucine spike" hypothesis. The dipeptide form of leucine may support this spike by leveraging PepT1-mediated transport, which operates independently of the amino acid transporter saturation that can limit free-form leucine absorption.

Additionally, Dileucine research suggests that once absorbed, the dipeptide is rapidly hydrolyzed to free leucine by dipeptidyl peptidases in enterocytes and plasma, meaning the ultimate substrate for mTORC1 activation is still leucine. The advantage conferred by the dipeptide form appears to be in the kinetics of delivery rather than any unique downstream signaling.

Key Research

The clearest human data on Dileucine comes from a double-blind randomized controlled trial published in Journal of Applied Physiology showing that Dileucine ingestion was more effective than leucine in stimulating muscle protein turnover in young males (PMID: 34323596). That does not mean Dileucine replaces total daily protein or progressive training, but it does support the core idea that the dipeptide form may deliver leucine in a more anabolic pattern than free leucine alone.

More recent work published in the Journal of the International Society of Sports Nutrition found that Dileucine-supplemented essential amino acids supported whole-body anabolism after resistance exercise, reinforcing the idea that Dileucine may be particularly relevant around training when the goal is to maximize the muscle protein synthetic response (PMID: 41321015).

Separately, broader leucine literature helps explain why this matters. Reviews on branched-chain amino acid signaling show that leucine is a key upstream trigger for translational control of protein synthesis through mTOR-related pathways (PMID: 16365087). And human work on leucine supplementation in lower-protein feeding contexts suggests that leucine availability can meaningfully influence the anabolic response when protein dosing is otherwise suboptimal (PMID: 22357161).

Clinical Evidence Summary

The body of evidence on Dileucine, while earlier stage than some established amino acid supplements, is mechanistically coherent and growing. Studies indicate that this dipeptide may support:

• Faster and more complete plasma leucine appearance following ingestion compared to free-form leucine at equivalent doses
• Greater activation of mTORC1 downstream signaling (p70S6K phosphorylation) in the first 60-120 minutes post-ingestion
• Improved muscle protein synthesis rates in resistance-trained individuals when consumed in the post-exercise window
• Potential anti-catabolic effects during caloric restriction by maintaining leucine availability during periods of reduced protein intake

What Makes the Wise Choice Supplements Version Different

Most amino acid supplements are not tested after manufacturing. They leave the production facility with a certificate of analysis from the ingredient supplier, which reflects the quality of the raw material at time of sale, not the finished product that ends up in your hands. We sent our Dileucine to Eurofins Scientific, one of the most respected independent analytical chemistry laboratories in the world, and had the finished product tested for identity, purity, and potency.

The results confirmed that our product contains what the label claims at the concentration the label claims. Our Certificate of Analysis is available on request. We offer 2000mg of pure Dileucine per serving with no fillers, no proprietary blends, and no undisclosed excipients. The only other ingredient is the container.

We also want to be transparent about what this product is not. It is not a magic muscle builder. Dileucine is an amino acid substrate. Its effectiveness depends on training stimulus, total daily protein intake, and overall recovery. It works best when added to an already-adequate protein intake as a precision tool to optimize the post-training MPS window. Used in context, the research suggests it may provide a meaningful edge. Used in isolation without training or adequate nutrition, it will not produce results.

Shop Dileucine 2000mg per Serving

Citations

1. Dileucine ingestion is more effective than leucine in stimulating muscle protein turnover in young males: a double blind randomized controlled trial. J Appl Physiol (1985). 2021. PMID: 34323596
2. Dileucine-supplemented essential amino acids support whole-body anabolism after resistance exercise and serum-stimulated cell-based anabolism. J Int Soc Sports Nutr. 2025. PMID: 41321015
3. Kimball SR, Jefferson LS. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr. 2006. PMID: 16365087
4. Casperson SL, Sheffield-Moore M, Hewlings SJ, Paddon-Jones D. Leucine supplementation chronically improves muscle protein synthesis in older adults consuming the RDA for protein. Clin Nutr. 2012. PMID: 22357161

BPC-157 Arginate (Body Protective Compound 157)

View the BPC-157 product

What Is BPC-157?

BPC-157 (Body Protective Compound 157) is a pentadecapeptide consisting of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a partial sequence of body protective compound, a protein found naturally in human gastric juice. The sequence was originally identified and isolated from human gastric juice by researchers studying gastric mucosal protection, which is where much of the foundational animal research has focused.

BPC-157 exists in several salt forms in commercial supplementation. The two most common are BPC-157 Acetate and BPC-157 Arginate. These are not equivalent. The salt form determines the peptide's stability at room temperature, its bioavailability under various pH conditions, and its shelf stability over time. This distinction is one of the most important and least discussed differences in the BPC-157 market.

The Arginate Salt Form: Why It Matters

BPC-157 Acetate is the form used in most animal studies and in the majority of commercial products. It is soluble in water and requires refrigeration to maintain stability. At room temperature over extended periods, acetate salt peptides are more prone to degradation. For a research compound in a laboratory setting, this is managed by proper storage protocols. For a supplement in a consumer's cabinet, it is a liability.

BPC-157 Arginate is a salt form where the peptide is paired with the amino acid L-Arginine rather than acetic acid. The arginate form confers significantly greater stability at ambient temperatures and does not require refrigeration to maintain potency over the shelf life of the product. This is why Wise Choice Supplements uses the arginate form exclusively. A BPC-157 capsule that is stable at room temperature through its shelf life delivers a more consistent dose than one that has partially degraded by the time it reaches the consumer.

Beyond stability, the arginate form may offer a bioavailability advantage. Arginine itself has vasodilatory properties via nitric oxide synthesis pathways, and preliminary research on peptide-arginine salts suggests improved mucosal absorption in the gastrointestinal tract. While this advantage has not been definitively quantified for BPC-157 specifically in large clinical trials, the stability advantage alone justifies the formulation choice.

Mechanism of Action

BPC-157 appears to operate through multiple overlapping mechanisms, which may explain the breadth of effects observed in preclinical research. Key mechanisms identified in the literature include:

• VEGF upregulation and angiogenesis: Studies indicate BPC-157 may stimulate expression of vascular endothelial growth factor, which drives new blood vessel formation (angiogenesis). In tissue repair, adequate vascularization is a rate-limiting step. Enhanced angiogenesis may accelerate the delivery of oxygen and nutrients to injured tissue.
• Nitric oxide system modulation: Research suggests BPC-157 interacts with the nitric oxide (NO) pathway. NO is a vasodilator and signaling molecule involved in vascular tone, tissue perfusion, and cellular stress response. Dysregulation of the NO system is implicated in a wide range of conditions.
• Growth hormone receptor modulation: Some studies propose that BPC-157 may interact with the GH-GHSR axis. This is speculative in the human context but is one proposed mechanism for its observed effects on tissue healing in animal models.
• Tendon and ligament fibroblast activation: In vitro and animal studies have shown BPC-157 may upregulate tendon fibroblast proliferation and the expression of growth factors including EGF receptor and FAK-paxillin signaling, which are involved in cell migration and wound healing.

Key Research

The published research on BPC-157 is dominated by rodent studies from researchers in Zagreb, Croatia, primarily from the laboratory of Predrag Sikiric, who has been the central figure in BPC-157 research for over two decades. This body of work is extensive and internally consistent, which adds credibility, while the near-complete reliance on animal models remains a limitation in terms of direct human applicability.

One of the best-known mechanistic papers is the 2011 Journal of Applied Physiology study showing that BPC-157 promoted tendon outgrowth, cell survival, and cell migration in experimental models of tendon healing (PMID: 21030672). This is one of the core papers behind the peptide's reputation in connective tissue discussions.

A 2019 review in Cell and Tissue Research summarized the musculoskeletal literature and argued that BPC-157 may accelerate soft-tissue healing across tendon, ligament, muscle, and bone models, while also highlighting that most of the evidence remains preclinical (PMID: 30915550).

Additional review literature has focused on angiogenic signaling and wound repair more broadly, tying BPC-157 to vascular responses, nitric oxide modulation, and tissue remodeling pathways that may help explain its recurring effects across different injury models (PMIDs: 29998800, 34267654).

Clinical Evidence and Limitations

It is important to state clearly: as of the time of writing, peer-reviewed human clinical trial data on BPC-157 is limited. The overwhelmingly positive effects seen in animal studies have not yet been confirmed in randomized controlled trials in humans. This does not mean the compound is ineffective in humans. It means the human evidence is not yet at the level required for us to make definitive efficacy claims.

What research does support is that the peptide is detectable after oral administration in animal models, that it reaches systemic circulation, and that it produces measurable physiological effects. The mechanistic coherence of the proposed pathways and the consistent direction of effect in animal research make BPC-157 one of the more scientifically interesting peptides available as a supplement. Human trials are underway, and this is an area of rapidly evolving research.

What Makes the Wise Choice Supplements Version Different

Our BPC-157 is manufactured as the arginate salt form (BPC-157 Arginate), not the acetate form used in most competitor products. This means room-temperature stability and consistent potency through the shelf life of the product. We use Janoshik Analytical, an independent laboratory specializing in peptide analysis, to verify identity and purity of the finished product. Our Certificate of Analysis confirms the presence and concentration of BPC-157 Arginate at the labeled dose of 500mcg per capsule.

We offer 120 capsules per bottle at 500mcg per capsule. The acetate form on the market is almost always sold at lower per-capsule doses or in raw powder form requiring reconstitution. Our oral capsule format with arginate salt allows for consistent, measured daily dosing without the stability concerns associated with acetate-based products.

Shop BPC-157 Arginate 500mcg

Citations

1. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011. PMID: 21030672
2. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. PMID: 30915550
3. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018. PMID: 29998800
4. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PMID: 34267654
5. BPC 157 and blood vessels. Curr Pharm Des. 2014. PMID: 23782145

Lactobacillus rhamnosus GG (LGG)

View the LGG Probiotic product

What Is LGG?

Lactobacillus rhamnosus GG (LGG) is arguably the most extensively studied probiotic strain in human clinical research. It was first isolated in 1985 by Sherwood Gorbach and Barry Goldin at Tufts University, and the GG in its name stands for their initials. LGG has been the subject of more than 1,000 published human studies, including over 200 randomized controlled trials, covering outcomes ranging from gastrointestinal health to immune function to metabolic markers.

This matters because most probiotic products on the market contain strains that have been studied minimally or not at all in human trials. Probiotic strain effects are not interchangeable. A result in Lactobacillus acidophilus cannot be extrapolated to Lactobacillus rhamnosus GG, and a result in one rhamnosus strain cannot be extrapolated to another. The clinical evidence for LGG specifically is among the strongest available for any single probiotic strain.

Mechanism of Action

LGG exerts its effects through multiple well-characterized mechanisms:

• Colonization and barrier reinforcement: LGG produces specific pili-like structures (SpaCBA fimbriae) that help it adhere to intestinal epithelial cells more effectively than many competing strains. This colonization ability supports mucosal persistence and helps explain why LGG is one of the best-characterized strains for gut barrier support and host interaction (PMID: 25186587).
• Immunomodulation: LGG interacts with intestinal immune cells and pattern-recognition systems in ways that may help modulate cytokine balance and barrier function. Review literature over the last three decades consistently identifies immune regulation as one of the central mechanisms behind LGG's clinical relevance (PMID: 30741841).
• Metabolic and ecological effects in the gut: Like other well-studied probiotics, LGG participates in the microbial ecology of the intestine, helping shape a more favorable gut environment through competitive exclusion, production of organic acids, and interaction with resident microbiota. Not every effect is unique to LGG, but LGG is one of the strains with the strongest human evidence base behind these general probiotic mechanisms.
• Competitive exclusion: By occupying mucosal binding sites and producing bacteriocins and organic acids, LGG may suppress the colonization and growth of pathogenic microorganisms including Clostridium difficile, Escherichia coli, and Salmonella species in preclinical and clinical studies.

Key Research

A 2019 review titled Thirty Years of Lactobacillus rhamnosus GG is one of the best summaries of the strain's evidence base and covers the areas where LGG has the strongest support, including gastrointestinal resilience, pediatric use, antibiotic-associated diarrhea, and broader host-microbe interaction science (PMID: 30741841).

In pediatrics, a 2016 review focused specifically on probiotics for prevention of antibiotic-associated diarrhea in children and identified LGG as one of the best-supported strains in that setting (PMID: 26756877). A 2020 Cochrane review on probiotics for acute infectious diarrhea adds broader support for probiotic utility in that category, while still underscoring the importance of strain specificity and study design quality (PMID: 33295643).

LGG has also been studied outside of simple gut comfort outcomes. For example, a randomized placebo-controlled trial in infancy evaluated LGG in atopic dermatitis, and more recent work has continued to explore immune-related applications of the strain in pediatric settings (PMIDs: 17919141, 36003050). The take-home point is not that LGG is a cure-all. It is that LGG is one of the few probiotic strains with a genuinely deep human literature.

CFU Count and Why It Matters

CFU stands for colony-forming units, the standard measure of viable probiotic bacteria per serving. Most probiotic research uses doses in the range of 1-100 billion CFU. Lower doses in the 1-5 billion range have shown benefits for mild gastrointestinal outcomes. Higher doses (10-30 billion CFU) are used in studies targeting more significant clinical endpoints.

A key consideration that many probiotic labels obscure is whether the CFU count stated is "at time of manufacture" or "at time of expiry." CFU counts decline during storage, and a product guaranteeing 30 billion CFU at manufacture may deliver significantly fewer viable bacteria by the time it reaches the consumer and is used. Look for labels that state CFU "at time of use" or "through end of shelf life."

What Makes the Wise Choice Supplements Version Different

Our LGG probiotic delivers 30 billion CFU of verified Lactobacillus rhamnosus GG per serving in a 90-capsule format providing 90 servings. We use the genuine LGG strain, which carries the documented research base described above, rather than a generic or unnamed Lactobacillus rhamnosus strain. Many products on the market contain L. rhamnosus without specifying GG, which means the clinical evidence for LGG specifically may not apply to those products.

At 30 billion CFU per capsule, our product is dosed at the upper range commonly used in published clinical studies, giving you a dose that aligns with the research rather than one calibrated to minimize manufacturing costs. At $23.99 for 90 servings, this represents a competitive price point for a clinically dosed, strain-verified probiotic.

Shop LGG Probiotic 30 Billion CFU

Citations

1. Segers ME, Lebeer S. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019. PMID: 30741841
2. Szajewska H, Kolodziej M. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2016. PMID: 26756877
3. Collinson S, Deans A, Padua-Zamora A, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020. PMID: 33295643
4. Viljanen M, Kuitunen M, Haahtela T, et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy. 2007. PMID: 17919141
5. Heine RG, et al. Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. Pediatr Allergy Immunol. 2022. PMID: 36003050
6. Lebeer S, et al. Towards a better understanding of Lactobacillus rhamnosus GG-host interactions. Microb Cell Fact. 2014. PMID: 25186587

Sea Moss (Chondrus crispus / Genus Gracilaria)

What Is Sea Moss?

Sea moss is a category of red algae harvested from Atlantic and Caribbean coastal waters. The most scientifically studied species is Chondrus crispus, commonly called Irish moss, though commercial sea moss products often derive from Gracilaria species harvested in the Caribbean. Both belong to the Rhodophyta (red algae) phylum and share a broadly similar nutritional profile, though there are meaningful differences in specific mineral concentrations and carrageenan content between species.

Sea moss has been consumed as food for centuries, particularly in coastal Ireland and the Caribbean, where it has traditionally been prepared as a gel or blended into beverages. Its renewed interest in modern wellness circles is largely attributable to its unusually dense mineral profile and its content of carrageenan polysaccharides, which have been studied for their effects on gut mucosa, lipid metabolism, and immune signaling.

Nutritional Profile and Mineral Density

Sea moss is one of the more nutritionally complete whole-food supplements available. Published nutritional analyses of Chondrus crispus show it contains measurable amounts of iodine, potassium, calcium, magnesium, iron, zinc, selenium, manganese, and phosphorus, as well as vitamins B2 (riboflavin), B9 (folate), and vitamin K. The iodine content is particularly notable: sea moss is one of the more concentrated dietary sources of iodine outside of seafood, and iodine is an essential micronutrient for thyroid hormone synthesis.

It is worth noting that mineral content in sea moss varies considerably depending on harvest location, season, processing method, and species. Farmed versus wild-harvested sea moss can differ substantially in iodine and heavy metal content. This variability is a significant quality control consideration for any sea moss product.

Mechanism of Action: Carrageenan and Sulfated Polysaccharides

The bioactive compounds in sea moss most studied for physiological effects are its sulfated polysaccharides, which include carrageenan, fucoidan, and related molecules. These are high-molecular-weight carbohydrates with negatively charged sulfate groups that interact with various biological receptors and signaling molecules.

Key proposed mechanisms include:

• Prebiotic fiber effects: Sea moss contains sulfated polysaccharides such as carrageenan that may influence the gut environment as fermentable fibers and bioactive matrix components. The strongest support here is mechanistic and review-based rather than large human intervention data, so this is best understood as biologically plausible rather than definitively proven in supplementation studies (PMIDs: 37396716, 24708958).
• Mucilaginous gastric protective effects: The gel-forming properties of carrageenan allow sea moss preparations to coat gastric mucosa, which may provide a physical protective effect against irritation and may support gastric transit. This mechanism is speculative in humans but is consistent with traditional use patterns.
• Thyroid support via iodine: Adequate iodine is essential for synthesis of thyroxine (T4) and triiodothyronine (T3), the primary thyroid hormones. Sea moss is a bioavailable iodine source. Iodine deficiency is the leading preventable cause of thyroid dysfunction globally, and sea moss may contribute to correcting marginal iodine status in populations that do not regularly consume seafood or iodized salt.
• Antioxidant and anti-inflammatory activity: Reviews on red macroalgae and Chondrus species describe antioxidant, structural, and bioactive properties that may help explain the interest in sea moss for wellness support. But most of this evidence comes from compositional work, cell models, or extract studies rather than high-quality human trials (PMIDs: 32992919, 38248672).

Key Research

A recent review in Marine Drugs summarized the chemical constituents and biological properties of Chondrus species, covering the mineral composition, polysaccharide content, and bioactive fractions that drive most of the scientific interest in sea moss (PMID: 38248672).

Separate review work on carrageenan biosynthesis and carrageenan applications helps explain why red algae attract so much attention in both food science and functional ingredient research. These papers are useful because they focus on the actual molecular families present in sea moss rather than repeating vague wellness claims (PMIDs: 37396716, 24708958).

Another relevant review from Marine Drugs examined minerals from macroalgae and highlighted both the opportunity and the risk in this category: seaweeds can be rich in iodine and trace minerals, but that same mineral-accumulating biology means sourcing and contaminant screening matter a lot (PMID: 30360515).

An important limitation of current sea moss research is that much of it uses extracted fractions, food-science models, or compositional analysis rather than finished consumer supplements. That is exactly why species verification and heavy metal testing matter so much in the real-world product category.

What Makes the Wise Choice Supplements Version Different

Sea moss is a category with significant quality variation. Heavy metal contamination (particularly arsenic and lead, which accumulate in algae from contaminated waters) is a genuine concern in lower-quality products. Sourcing and testing protocol are the critical differentiation factors here. We source our sea moss from verified supply chains and test the finished product for heavy metals and identity confirmation. The mineral density that makes sea moss nutritionally interesting also requires that the raw material comes from clean water sources.

Our sea moss product is a whole-plant preparation providing the full range of naturally occurring minerals, polysaccharides, and trace elements rather than an isolated carrageenan extract. This preserves the nutritional matrix in which these compounds naturally occur and which may influence their absorption and activity in ways that isolated extracts do not capture.

Citations

1. An Update on the Chemical Constituents and Biological Properties of Selected Species of an Underpinned Genus of Red Algae: Chondrus. Mar Drugs. 2024. PMID: 38248672
2. Carrageenan biosynthesis in red algae: A review. Cell Surf. 2023. PMID: 37396716
3. Necas J, Bartosikova L. Carrageenan: a natural seaweed polysaccharide and its applications. Carbohydr Polym. 2014. PMID: 24708958
4. Circuncisão AR, Catarino MD, Cardoso SM, Silva AMS. Minerals from Macroalgae Origin: Health Benefits and Risks for Consumers. Mar Drugs. 2018. PMID: 30360515
5. Therapeutic Uses of Red Macroalgae. Molecules. 2020. PMID: 32992919

Our Commitment to Scientific Honesty

We will not claim that our products cure, treat, or prevent any condition. We will not cite studies selectively to make weak evidence appear stronger than it is. We will tell you when the evidence is limited and what the limitations are. We believe that customers who understand the science make better decisions, and that informed customers are worth more to a brand than convinced ones.

If you have questions about the research behind any of our products, you can reach us directly. We read our own inbox.